Literature DB >> 17634902

Acute psychosis in systemic lupus erythematosus.

Simone Appenzeller1, Fernando Cendes, Lilian Tereza Lavras Costallat.   

Abstract

To evaluate the frequency and risk factors of acute psychosis in a large cohort of patients with systemic lupus erythematosous (SLE). To identify clinical and laboratory variables useful in differentiating acute psychosis as a primary manifestation of central nervous system (CNS) from corticosteroid induced psychosis. Five hundred and thirty seven consecutive patients with SLE were studied, with follow-up ranging from 4 to 8.8 years. A standardized medical history, neurological, rheumatologic, and psychiatric examinations and serologic testing were performed in all patients. The type and frequency of risk factors associated with acute psychosis as a primary manifestation of CNS system and corticosteroid induced psychosis was determined using multivariate regression with automatic backward stepwise selection. We identified acute psychosis in 89 of 520 (17.1%) SLE patients. Psychosis primary to CNS involvement was diagnosed in 59 of these patients, corticosteroid induced psychosis in 28 and primary psychotic disorder not related to SLE or medication in two patients. Psychosis secondary to SLE at disease onset occurred in 19 patients and was associated with disease activity (p = 0.001; OR = 2.4; CI = 1.5-6.2). Psychosis during follow-up of SLE was observed in 40 patients and associated with positive antiphospholipid antibodies (p = 0.004; OR = 3.2; CI = 1.9-4.5) and less frequently with renal (p = 0.002; OR = 1.9; CI = 0.0-0.6) and cutaneous (p = 0.04; OR = 1.1; CI = 0.0-0.8) involvement. We identified 28 patients with 38 episodes of psychosis associated with corticosteroid therapy. All the patients had severe active disease and ten of these patients had hypoalbuminemia when psychosis developed. At the time of psychotic event, all the patients were taking prednisone in doses varying from 0.75 to 1 mg/kg day(-1). Psychosis resolved after tapering prednisone down in all patients. Acute psychosis related to SLE was observed in 11.3% of our cohort. Recurrence of primary psychosis was associated with other CNS manifestations related to SLE.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17634902     DOI: 10.1007/s00296-007-0410-x

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  33 in total

1.  Neuropsychiatric manifestations and their clinical associations in southern Chinese patients with systemic lupus erythematosus.

Authors:  C C Mok; C S Lau; R W Wong
Journal:  J Rheumatol       Date:  2001-04       Impact factor: 4.666

Review 2.  Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome.

Authors:  Gisele Zandman-Goddard; Joab Chapman; Yehuda Shoenfeld
Journal:  Semin Arthritis Rheum       Date:  2007-01-26       Impact factor: 5.532

3.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

Authors:  C Bombardier; D D Gladman; M B Urowitz; D Caron; C H Chang
Journal:  Arthritis Rheum       Date:  1992-06

4.  Prednisone side-effects and serum-protein levels. A collaborative study.

Authors:  G P Lewis; W J Jusko; L Graves; C W Burke
Journal:  Lancet       Date:  1971-10-09       Impact factor: 79.321

Review 5.  Acute central nervous system complications after pulse steroid therapy in patients with systemic lupus erythematosus.

Authors:  A J Wysenbeek; L Leibovici; J Zoldan
Journal:  J Rheumatol       Date:  1990-12       Impact factor: 4.666

Review 6.  Steroid psychosis: a review.

Authors:  François Sirois
Journal:  Gen Hosp Psychiatry       Date:  2003 Jan-Feb       Impact factor: 3.238

Review 7.  The central nervous system in systemic lupus erythematosus. Part 1. Clinical syndromes: a literature investigation.

Authors:  F G I Jennekens; L Kater
Journal:  Rheumatology (Oxford)       Date:  2002-06       Impact factor: 7.580

8.  Neuropsychiatric syndromes in lupus: prevalence using standardized definitions.

Authors:  R L Brey; S L Holliday; A R Saklad; M G Navarrete; D Hermosillo-Romo; C L Stallworth; C R Valdez; A Escalante; I del Rincón; G Gronseth; C B Rhine; P Padilla; D McGlasson
Journal:  Neurology       Date:  2002-04-23       Impact factor: 9.910

9.  Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986.

Authors:  E N Harris; A E Gharavi; S P Patel; G R Hughes
Journal:  Clin Exp Immunol       Date:  1987-04       Impact factor: 4.330

Review 10.  Ribosomal P antibodies and CNS lupus.

Authors:  M Reichlin
Journal:  Lupus       Date:  2003       Impact factor: 2.911

View more
  17 in total

1.  Psychotic Symptoms in a Child with Long Standing SLE Nephritis: Neuropsychiatric Manifestation or Sequelae to Lupus?

Authors:  Ananya Mahapatra; Pawan Sharma; Rajesh Sagar
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2016-05-01

Review 2.  Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications.

Authors:  Melinda Liu; Yuan Yu M Huang; Sylvia Hsu; Joseph S Kass
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

3.  Acute psychosis and type 2 diabetes mellitus:should screening guidelines be revised?

Authors:  Leah K Bauer; Lawson R Wulsin; Gina Guadagno
Journal:  Prim Care Companion CNS Disord       Date:  2011

4.  The risk benefit ratio of glucocorticoids in SLE: have things changed over the past 40 years?

Authors:  G Stojan; M Petri
Journal:  Curr Treatm Opt Rheumatol       Date:  2017-07-27

Review 5.  Neuropsychiatric manifestations in systemic lupus erythematosus: epidemiology, pathophysiology and management.

Authors:  Mariana Postal; Lilian T L Costallat; Simone Appenzeller
Journal:  CNS Drugs       Date:  2011-09-01       Impact factor: 5.749

Review 6.  Corticosteroid-induced neuropsychiatric disorders: review and contrast with neuropsychiatric lupus.

Authors:  Samir D Bhangle; Neil Kramer; Elliot D Rosenstein
Journal:  Rheumatol Int       Date:  2013-04-16       Impact factor: 2.631

7.  Psychosis in a young female - a diagnostic and therapeutic challenge.

Authors:  Sharmin Nizam; Andrew Gough
Journal:  JRSM Short Rep       Date:  2010-08-31

8.  Secondary psychoses: an update.

Authors:  Matcheri S Keshavan; Yoshio Kaneko
Journal:  World Psychiatry       Date:  2013-02       Impact factor: 49.548

Review 9.  Neuropsychiatric systemic lupus erythematosus: pathogenesis and biomarkers.

Authors:  Hélène Jeltsch-David; Sylviane Muller
Journal:  Nat Rev Neurol       Date:  2014-09-09       Impact factor: 42.937

10.  Neuropsychiatric systemic lupus erythematosus.

Authors:  Alexandra Popescu; Amy H Kao
Journal:  Curr Neuropharmacol       Date:  2011-09       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.